CLINICAL EVALUATION OF AYUSH PE EYE DROPS IN THE MANAGEMENT OF ACUTE ALLERGIC CONJUNCTIVITIS: AN OPEN LABEL SINGLE ARM PROSPECTIVE MULTICENTER STUDY

IntroductionOcular allergy is one of the most common prevalent clinical conditions in the world with a rapid increase in the past few years. It has a multifactorial etiology and is a conjunctival inflammatory response due to IgE mediated mast cell activation. The disease is characterized by itching, redness, burning sensation and watering of eyes which go off and on. Due to the side effects of contemporary management, a safe, cost effective user tolerable potent Ayurveda drug AYUSH PE was developed after undergoing all quality assurance tests.Materials and MethodsA multicenter study open labeled single group prospective study was conducted at four research institutes of the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH from May 2019 to December 2019. A total of 221 participants were enrolled based on purposive sampling at four study sites. The participants were evaluated based on the signs and symptoms of allergic conjunctivitis using the VAS score (0-100). Two drops of AYUSH PE Eye drops were instilled to the affected eyes six times a day and the patients were reviewed after one week. The medicine was then stopped and a second follow up was done again after one more week.ResultsTotal of 217 participants were analyzed for the outcomes. Statistically significant changes was observed in all the assessment parameters viz: itching, redness of eyes, watery discharge, lid swelling, foreign body sensation, liking for warm touches, heaviness in eyes, feeling of stickiness in eyes, appearance of allergic hue in eyes, feeling of excessive cold in eyes and slimy secretions from eyes at 7th day (p-value &amp;lt;0.001) and at 14th day (p-value &amp;lt;0.001) as compared to baseline.ConclusionAYUSH PE drops are safe and effective and user tolerable eye drops in the management of acute allergic conjunctivitis.</p

CLINICAL EVALUATION OF AYUSH PE EYE DROPS IN THE MANAGEMENT OF ACUTE ALLERGIC CONJUNCTIVITIS: AN OPEN LABEL SINGLE ARM PROSPECTIVE MULTICENTER STUDY

Introduction Ocular allergy is one of the most common prevalent clinical conditions in the world with a rapid increase in the past few years. It has a multifactorial etiology and is a conjunctival inflammatory response due to IgE mediated mast cell activation. The disease is characterized by itching, redness, burning sensation and watering of eyes which go off and on. Due to the side effects of contemporary management, a safe, cost effective user tolerable potent Ayurveda drug AYUSH PE was developed after undergoing all quality assurance tests. Materials and Methods A multicenter study open labeled single group prospective study was conducted at four research institutes of the Central Council for Research in Ayurvedic Sciences (CCRAS), Ministry of AYUSH from May 2019 to December 2019. A total of 221 participants were enrolled based on purposive sampling at four study sites. The participants were evaluated based on the signs and symptoms of allergic conjunctivitis using the VAS score (0-100). Two drops of AYUSH PE Eye drops were instilled to the affected eyes six times a day and the patients were reviewed after one week. The medicine was then stopped and a second follow up was done again after one more week. Results Total of 217 participants were analyzed for the outcomes. Statistically significant changes was observed in all the assessment parameters viz: itching, redness of eyes, watery discharge, lid swelling, foreign body sensation, liking for warm touches, heaviness in eyes, feeling of stickiness in eyes, appearance of allergic hue in eyes, feeling of excessive cold in eyes and slimy secretions from eyes at 7th day (p-value &lt;0.001) and at 14th day (p-value &lt;0.001) as compared to baseline. Conclusion AYUSH PE drops are safe and effective and user tolerable eye drops in the management of acute allergic conjunctivitis

Regulated expression of PTPRJ/CD148 and an antisense long noncoding RNA in macrophages by proinflammatory stimuli

PTPRJ/CD148 is a tyrosine phosphatase that has tumour suppressor-like activity. Quantitative PCR of various cells and tissues revealed that it is preferentially expressed in macrophage-enriched tissues. Within lymphoid tissues immunohistochemistry revealed that PTPRJ/CD148 co-localised with F4/80, indicating that macrophages most strongly express the protein. Macrophages express the highest basal level of ptprj, and this is elevated further by treatment with LPS and other Toll-like receptor ligands. In contrast, CSF-1 treatment reduced basal and stimulated Ptprj expression in human and mouse cells, and interferon also repressed Ptprj expression. We identified a 1006 nucleotide long noncoding RNA species, Ptprj-as1 that is transcribed antisense to Ptprj. Ptprj-as1 was highly expressed in macrophage-enriched tissue and was transiently induced by Toll-like receptor ligands with a similar time course to Ptprj. Finally, putative transcription factor binding sites in the promoter region of Ptprj were identified